EXPLORING THE ROLE OF GENETIC MARKERS IN PREDICTING TREATMENT RESPONSES IN OVARIAN CANCER: A MULTI-CENTER STUDY

Abstract

This study investigates the baseline characteristics, treatment patterns, and the association of genetic markers with treatment response in 500 ovarian cancer patients, categorized into 320 responders and 180 non-responders. The average age of responders was significantly lower (52.8 ± 9.5 years) than that of non-responders (56.5 ± 11.4 years, p = 0.03). BRCA1/2 mutations were notably more frequent in responders (34.4%) than in non-responders (22.2%, p = 0.005), demonstrating a strong association with positive treatment outcomes (odds ratio: 2.16, p = 0.001). TP53 mutations, present in 40% of the population, showed a non-significant association with treatment response (odds ratio: 1.12, p = 0.57), while PTEN loss was observed in 16% of patients with no significant impact on treatment efficacy (p = 0.83). Chemotherapy remained the preferred form of treatment among all patients within the study population. Stratified by BRCA1/2 mutation status, we observed no differences in overall survival within 30 months, and the survival curves are practically superimposable beyond 30 months. These results underscore the role of BRCA1/2 mutations in the treatment management of ovarian cancer patients.